<?xml version='1.0' encoding='utf-8'?>
<document id="29694732"><sentence text="Pharmacokinetic Interaction Between Fingolimod and Carbamazepine in Healthy Subjects."><entity charOffset="36-46" id="DDI-PubMed.29694732.s1.e0" text="Fingolimod" /><entity charOffset="51-64" id="DDI-PubMed.29694732.s1.e1" text="Carbamazepine" /><pair ddi="false" e1="DDI-PubMed.29694732.s1.e0" e2="DDI-PubMed.29694732.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29694732.s1.e0" e2="DDI-PubMed.29694732.s1.e1" /></sentence><sentence text="This open-label, single-sequence study in healthy subjects investigated the effects of steady-state carbamazepine on the pharmacokinetic (PK) profile of a single 2-mg dose of fingolimod"><entity charOffset="100-113" id="DDI-PubMed.29694732.s2.e0" text="carbamazepine" /><entity charOffset="175-185" id="DDI-PubMed.29694732.s2.e1" text="fingolimod" /><pair ddi="false" e1="DDI-PubMed.29694732.s2.e0" e2="DDI-PubMed.29694732.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29694732.s2.e0" e2="DDI-PubMed.29694732.s2.e1" /></sentence><sentence text=" In period 1, a single oral dose of fingolimod 2 mg (day 1) was followed by PK and safety assessments up to 36 days"><entity charOffset="36-46" id="DDI-PubMed.29694732.s3.e0" text="fingolimod" /></sentence><sentence text=" In period 2, carbamazepine was administered in flexible, up-titrated doses (600 mg twice daily maximum) for 49 days" /><sentence text=" Fingolimod was administered on day 35, followed by a study completion evaluation (day 71)"><entity charOffset="1-11" id="DDI-PubMed.29694732.s5.e0" text="Fingolimod" /></sentence><sentence text=" The PK analysis included 23 of 26 of the enrolled subjects (88" /><sentence text="5%)" /><sentence text=" Coadministration of fingolimod at steady-state carbamazepine concentrations resulted in increased fingolimod CL/F by 67% through the induction of CYP3A4, a cytochrome with negligible involvement in fingolimod clearance in an uninduced state"><entity charOffset="21-31" id="DDI-PubMed.29694732.s8.e0" text="fingolimod" /><entity charOffset="48-61" id="DDI-PubMed.29694732.s8.e1" text="carbamazepine" /><pair ddi="false" e1="DDI-PubMed.29694732.s8.e0" e2="DDI-PubMed.29694732.s8.e0" /><pair ddi="false" e1="DDI-PubMed.29694732.s8.e0" e2="DDI-PubMed.29694732.s8.e1" /></sentence><sentence text=" Fingolimod Cmax was reduced by 18% and AUCinf by 40%, as was T1/2 (106 vs 163 hours)"><entity charOffset="1-11" id="DDI-PubMed.29694732.s9.e0" text="Fingolimod" /></sentence><sentence text=" A similar trend was observed for fingolimod-P"><entity charOffset="34-46" id="DDI-PubMed.29694732.s10.e0" text="fingolimod-P" /></sentence><sentence text=" Models linking fingolimod-P blood concentrations to lymphocyte count or annual relapse rate suggest that such a decrease would have a low impact on the treatment effect"><entity charOffset="16-28" id="DDI-PubMed.29694732.s11.e0" text="fingolimod-P" /></sentence><sentence text=" However, in the absence of efficacy data of fingolimod at doses lower than the therapeutic dose, their coadministration should be used with caution"><entity charOffset="45-55" id="DDI-PubMed.29694732.s12.e0" text="fingolimod" /></sentence><sentence text="" /></document>